Placental Stem Cells for ARDS Oxygenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for SARS-CoV-2 related acute respiratory failure and ARDS (COVID-19) lack effective solutions to improve oxygenation, reduce the need for mechanical ventilation and ECMO, and decrease mortality rates.
Innovation Solution
Administration of a therapeutically effective amount of tissue culture plastic-adherent placental cells, specifically CD34−, CD10+, CD105+, CD200+ placental stem cells, formulated as a pharmaceutical composition, either intravenously or in specific dosages ranging from 1×10^5 to 1×10^10 cells, to treat SARS-CoV-2 related acute respiratory failure and ARDS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for SARS-CoV-2 related acute respiratory failure and ARDS are used, then standard care protocols are maintained, but oxygenation improvement is insufficient and mortality rates remain high
Solution Approach 1:
The patent introduces placental stem cells as an intermediary therapeutic agent that mediates between the harmful viral infection and the patient's respiratory system. These cells act as a biological mediator that reduces inflammation, prevents lung tissue damage, and improves oxygenation without directly attacking the virus, thereby resolving the contradiction between maintaining standard care and achieving improved treatment outcomes
Solution Approach 2:
The treatment changes the physiological parameters of the respiratory system by introducing placental stem cells that secrete growth factors and cytokines. This alters the inflammatory response parameters, improves gas exchange parameters, and changes the overall course of the disease from progressive deterioration to stabilization and recovery, thereby improving treatment effectiveness
2Reliability
If mechanical ventilation and ECMO are used to treat ARDS, then oxygenation is maintained, but the duration of intensive care and hospital stay increases
Solution Approach 1:
The patent applies preliminary action by administering placental stem cells early in the disease course, before the patient requires mechanical ventilation or ECMO. This preventive therapeutic intervention stabilizes the respiratory system in advance, preventing the need for prolonged life support and reducing the duration of intensive care stay while maintaining adequate oxygenation
3Reliability
If higher doses of placental stem cells are administered, then treatment efficacy increases, but the complexity of dosage determination increases
Solution Approach 1:
The patent establishes specific dosage parameters (1×10^5 to 1×10^10 cells) and administration protocols that standardize the treatment. By defining concrete dosage ranges and administration schedules, the patent transforms the complex biological variable of cell dosage into manageable, standardized parameters that can be consistently applied, thereby maintaining treatment efficacy while reducing determination complexity
Data Source
AI summary
Provided herein are methods of using CD10+, CD34−, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of SARS-CoV-2 related acute respiratory failure and ARDS (COVID-19).